Cargando…
MiR-130a-3p Alleviates Inflammatory and Fibrotic Phases of Pulmonary Fibrosis Through Proinflammatory Factor TNF-α and Profibrogenic Receptor TGF-βRII
Pulmonary fibrosis (PF) is a progressive disease characterized by extracellular matrix (ECM) deposition that destroys the normal structure of the lung parenchyma, which is classified into two successive inflammatory and fibrotic phases. To investigate the anti-inflammatory and anti-fibrotic roles of...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006815/ https://www.ncbi.nlm.nih.gov/pubmed/35431964 http://dx.doi.org/10.3389/fphar.2022.863646 |
_version_ | 1784686739811467264 |
---|---|
author | Ding, Yan Hou, Yapeng Liu, Yanhong Yu, Tong Cui, Yong Nie, Hongguang |
author_facet | Ding, Yan Hou, Yapeng Liu, Yanhong Yu, Tong Cui, Yong Nie, Hongguang |
author_sort | Ding, Yan |
collection | PubMed |
description | Pulmonary fibrosis (PF) is a progressive disease characterized by extracellular matrix (ECM) deposition that destroys the normal structure of the lung parenchyma, which is classified into two successive inflammatory and fibrotic phases. To investigate the anti-inflammatory and anti-fibrotic roles of miR-130a-3p in mice with bleomycin (BLM)-induced PF and the underlying mechanism, we performed single-cell RNA-sequencing analysis, which demonstrated that BLM increased/decreased the percentage of macrophages and fibroblasts/epithelial cells in PF lungs, respectively. The differentially expressed genes were enriched in PPAR signaling pathway and lysosome, ECM–receptor interaction and ribosome, and metabolism reaction. Time-course studies demonstrated that the inflammation-related factors increased significantly at day 7 (inflammatory phase), whereas the fibrosis-related factors increased at day 28 (fibrotic phase) after BLM exposure. Meanwhile, miR-130a-3p could ameliorate pulmonary lesions by downregulating the secretion of inflammatory cytokines (IL-1β, IL-6, TNF-α, and TGF-β1) and the deposition of ECM (α-SMA, FN, HYP, and collagen) in the inflammatory and fibrotic phase, respectively. In the LPS-induced inflammatory cell model, the upregulation of miR-130a-3p was mainly achieved by the activation of the NF-κB signaling pathway, which suppressed the proinflammatory factor TNF-α. Comparatively, the TGF-β/Smad signaling pathway was inhibited by miR-130a-3p targeting TGF-βRII in the TGF-β1-deduced fibrotic cell model. The evidence supports that miR-130a-3p exerts an anti-inflammatory and anti-fibrotic effect in BLM-induced PF, implying a potential pharmacological agent in the therapy of PF patients. |
format | Online Article Text |
id | pubmed-9006815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90068152022-04-14 MiR-130a-3p Alleviates Inflammatory and Fibrotic Phases of Pulmonary Fibrosis Through Proinflammatory Factor TNF-α and Profibrogenic Receptor TGF-βRII Ding, Yan Hou, Yapeng Liu, Yanhong Yu, Tong Cui, Yong Nie, Hongguang Front Pharmacol Pharmacology Pulmonary fibrosis (PF) is a progressive disease characterized by extracellular matrix (ECM) deposition that destroys the normal structure of the lung parenchyma, which is classified into two successive inflammatory and fibrotic phases. To investigate the anti-inflammatory and anti-fibrotic roles of miR-130a-3p in mice with bleomycin (BLM)-induced PF and the underlying mechanism, we performed single-cell RNA-sequencing analysis, which demonstrated that BLM increased/decreased the percentage of macrophages and fibroblasts/epithelial cells in PF lungs, respectively. The differentially expressed genes were enriched in PPAR signaling pathway and lysosome, ECM–receptor interaction and ribosome, and metabolism reaction. Time-course studies demonstrated that the inflammation-related factors increased significantly at day 7 (inflammatory phase), whereas the fibrosis-related factors increased at day 28 (fibrotic phase) after BLM exposure. Meanwhile, miR-130a-3p could ameliorate pulmonary lesions by downregulating the secretion of inflammatory cytokines (IL-1β, IL-6, TNF-α, and TGF-β1) and the deposition of ECM (α-SMA, FN, HYP, and collagen) in the inflammatory and fibrotic phase, respectively. In the LPS-induced inflammatory cell model, the upregulation of miR-130a-3p was mainly achieved by the activation of the NF-κB signaling pathway, which suppressed the proinflammatory factor TNF-α. Comparatively, the TGF-β/Smad signaling pathway was inhibited by miR-130a-3p targeting TGF-βRII in the TGF-β1-deduced fibrotic cell model. The evidence supports that miR-130a-3p exerts an anti-inflammatory and anti-fibrotic effect in BLM-induced PF, implying a potential pharmacological agent in the therapy of PF patients. Frontiers Media S.A. 2022-03-30 /pmc/articles/PMC9006815/ /pubmed/35431964 http://dx.doi.org/10.3389/fphar.2022.863646 Text en Copyright © 2022 Ding, Hou, Liu, Yu, Cui and Nie. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Ding, Yan Hou, Yapeng Liu, Yanhong Yu, Tong Cui, Yong Nie, Hongguang MiR-130a-3p Alleviates Inflammatory and Fibrotic Phases of Pulmonary Fibrosis Through Proinflammatory Factor TNF-α and Profibrogenic Receptor TGF-βRII |
title | MiR-130a-3p Alleviates Inflammatory and Fibrotic Phases of Pulmonary Fibrosis Through Proinflammatory Factor TNF-α and Profibrogenic Receptor TGF-βRII |
title_full | MiR-130a-3p Alleviates Inflammatory and Fibrotic Phases of Pulmonary Fibrosis Through Proinflammatory Factor TNF-α and Profibrogenic Receptor TGF-βRII |
title_fullStr | MiR-130a-3p Alleviates Inflammatory and Fibrotic Phases of Pulmonary Fibrosis Through Proinflammatory Factor TNF-α and Profibrogenic Receptor TGF-βRII |
title_full_unstemmed | MiR-130a-3p Alleviates Inflammatory and Fibrotic Phases of Pulmonary Fibrosis Through Proinflammatory Factor TNF-α and Profibrogenic Receptor TGF-βRII |
title_short | MiR-130a-3p Alleviates Inflammatory and Fibrotic Phases of Pulmonary Fibrosis Through Proinflammatory Factor TNF-α and Profibrogenic Receptor TGF-βRII |
title_sort | mir-130a-3p alleviates inflammatory and fibrotic phases of pulmonary fibrosis through proinflammatory factor tnf-α and profibrogenic receptor tgf-βrii |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006815/ https://www.ncbi.nlm.nih.gov/pubmed/35431964 http://dx.doi.org/10.3389/fphar.2022.863646 |
work_keys_str_mv | AT dingyan mir130a3palleviatesinflammatoryandfibroticphasesofpulmonaryfibrosisthroughproinflammatoryfactortnfaandprofibrogenicreceptortgfbrii AT houyapeng mir130a3palleviatesinflammatoryandfibroticphasesofpulmonaryfibrosisthroughproinflammatoryfactortnfaandprofibrogenicreceptortgfbrii AT liuyanhong mir130a3palleviatesinflammatoryandfibroticphasesofpulmonaryfibrosisthroughproinflammatoryfactortnfaandprofibrogenicreceptortgfbrii AT yutong mir130a3palleviatesinflammatoryandfibroticphasesofpulmonaryfibrosisthroughproinflammatoryfactortnfaandprofibrogenicreceptortgfbrii AT cuiyong mir130a3palleviatesinflammatoryandfibroticphasesofpulmonaryfibrosisthroughproinflammatoryfactortnfaandprofibrogenicreceptortgfbrii AT niehongguang mir130a3palleviatesinflammatoryandfibroticphasesofpulmonaryfibrosisthroughproinflammatoryfactortnfaandprofibrogenicreceptortgfbrii |